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Abstract (249) 
Background  
The IFCC Committee for Standardization of Thyroid Function Tests developed a 
global harmonization approach for thyroid-stimulating hormone measurements. It is 
based on a multi-assay method comparison study with clinical samples and target 
setting with a robust factor analysis method. Here we describe the Phase IV method 
comparison and reference interval (RI) studies conducted with the objective to 
recalibrate the participating assays and supply the proof-of-concept.  
Methods  
Fourteen manufacturers measured the harmonization and RI panel; 4 of them 
quantified the harmonization and first follow-up panel in parallel. All recalibrated their 
assays to the statistically inferred targets. For validation, we used desirable 
specifications from the biological variation for the bias and total error (TE). The RI 
measurements were done with the assays’ current calibrators, but data were also 
reported after transformation to the new calibration status. We estimated the pre- and 
post-recalibration RIs with a non-parametric bootstrap procedure.  
Results 
After recalibration, 14 of 15 assays met the bias specification with 95% confidence; 8 
assays complied with the TE specification. The CV of the assay means for the 
harmonization panel was reduced from 9.5% to 4.2%. The RI study showed improved 
uniformity after recalibration: the ranges (i.e., maximum differences) exhibited by the 
assay-specific 2.5, 50 and 97.5 percentile estimates were reduced from 0.27, 0.89 
and 2.13 mIU/L to 0.12 , 0.29 and 0.77 mIU/L.  
Conclusion 
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We showed that harmonization increased the agreement of results from the 
participating immunoassays, and may allow them to adopt a more uniform RI in the 
future. 
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Introduction  
Given the prevalence and gravity of thyroid disorders, timely diagnosis, initiation and 
monitoring of therapy are important to restrict the impact of the disease on public 
health. Measurement of serum thyroid hormone concentrations is an indispensable 
tool to confirm the disease, particularly because the clinical symptoms often resemble 
other disorders or are subtle in case of subclinical thyroid dysfunction (1, 2). The 
main clinical scenarios for measurement of serum thyroid-stimulating hormone (TSH) 
are screening for thyroid dysfunction, evaluation of thyroid hormone replacement for 
primary hypothyroidism, and assessment of suppressive therapy in patients with 
follicular cell-derived thyroid cancer. Professional practice guidelines incorporate 
laboratory testing of the thyroid function in patient care (3-7). Reference intervals (RI) 
reported along with the laboratory data are an integral part of the interpretation 
process (8, 9). Since many laboratory measurements are not yet comparable, RIs are 
typically established for each assay and are considered assay-specific. For 
physicians who only use one laboratory and are aware of these technical issues, this 
practice is fine. However, those who request test results from different laboratories, 
are often faced with challenges due to different RIs. Assay-specific RIs are also 
problematic for patients who regularly move between geographic locations and/or are 
seen by different doctors (10). More generally, assay-specific measurement results 
prevent the development of modern public health standards, such as clinical 
guidelines quoting fixed decision limits and integration of electronic patient records in 
the health care system (11). Paramount to the goal of using common RIs is the 
establishment of metrological traceability of in-vitro diagnostic (IVD) medical devices 
– also called standardization (12-14). As IFCC’s Committee for Standardization of 
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Thyroid Function Tests (C-STFT) members, we decided to focus our efforts on 
immunoassays for TSH and free thyroxine in partnership with the IVD industry (15). 
Our premise was that, if possible, we should adhere to the concept for traceability 
recommended by the International Organization for Standardization (16). Although a 
reference measurement procedure existed for free thyroxine, we considered this 
option for TSH unlikely and developed a pragmatic approach to harmonization rather 
than standardization (17, 18). To circumvent the often encountered commutability 
issues in establishing calibration traceability of IVD assays, it was a premise for C-
STFT that harmonization should be done from a multi-assay method comparison 
study with a panel of native and clinically relevant samples (19-21). We developed a 
robust factor analysis method for estimation of the harmonization targets and 
demonstrated the equivalence of the approach to standardization to a reference 
measurement procedure (22, 23). 
Here we report on behalf of the C-STFT the most recent Phase IV studies in 
our TSH harmonization efforts in which we demonstrate that establishing calibration 
traceability of commercially available immunoassays enables the adoption of a more 
uniform reference interval for TSH.
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Materials and methods  
Panels of clinical samples  
To allow manufacturers to adjust their calibration to the harmonization basis we 
developed, we performed a new method comparison for Phase IV. We sourced 
samples from 2 commercial companies (in.vent Diagnostica GmbH; Solomon Park 
Research Laboratories) but also with the aid of 8 different outpatient thyroid clinics in 
Belgium, Japan and Australia. The goal was to obtain a harmonization and first 
follow-up panel each comprising samples with concentrations that reasonably cover 
the measurement intervals of the participating TSH immunoassays. C-STFT provided 
the eligibility and exclusion criteria (see the online Supplemental, Section 3). Blood 
(ca. 50 mL per donor) was collected in serum separator tubes to mimic routine 
conditions and locally processed into off-the-clot serum. Samples were stored at -
70°C and transported under dry ice to either the Europe- or USA-based company for 
aliquoting. The aliquots of the 1st follow-up panel are stored in the facilities of the 
National Institute for Biological Standards and Control (UK). For all collections the 
approval of a Bioethic Committee and written informed consent from patients were 
received. The de-identified samples were accompanied by a short description of the 
patients’ clinical background (type of thyroid dysfunction, comorbidities, 
surgery/treatment, ethnicity, gender, etc.). The TSH harmonization and first follow-up 
panels comprised 101 and 95 samples, respectively.  
For the RI study, 120 samples from American individuals were sourced under 
identical conditions from Solomon Park Research Laboratories. Selection criteria 
were negativity in anti-thyroperoxidase antibody screening and a serum TSH 
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concentration <10 mIU/L (cut-off recommended for starting with replacement therapy) 
(testing performed with the Tosoh AIA-2000 platform) (4, 5). 
 
Study participants  
Fourteen IVD manufacturers participated, each with one immunoassay (coding and 
further details in Table 1). 
 
Assignment of target values  
Two ‘targets’ – actually, two sets of 101 sample-specific value assignments – for the 
harmonization panel, referred to below (for historical reasons) as APTM-11 and 
APTM-4, were assigned using a robust factor analysis model (22). The first target, 
the APTM-11, was derived from the results reported by all manufacturers but 3, i.e., 
manufacturer E whose assay design was in contrast to that of all others not real 3rd 
generation, and N and O who joined the project 1 year after the validation of the 
target setting described in this report had been completed. The second target, APTM-
4, was based on the results of 4 manufacturers only (identified in Table 1), i.e., those 
who measured both the harmonization and first follow-up panel in the same run. The 
data from these 2 panels (n = 196) were pooled to statistically estimate the APTM-4 
targets. 
  
Study measurement protocol  
In the method comparison study, all IVD manufacturers quantified the harmonization 
panel. The samples were measured in a randomized sequence specified by us, in 
singleton on each of 2 days; the individual results were reported. The manufacturers 
also included their master calibrators (note, these are the calibrators used for in-
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house value assignment to the product calibrators) for measurement in parallel with 
the panel samples and according to the same protocol. In the RI study, which was 
performed minimum 6 months after the method comparison, the samples were 
measured in order of ascending ID number, in singleton and within run. Organization 
and interpretation of internal QC was left to the discretion of each manufacturer.  
 
Recalibration of immunoassays  
We calculated both the APTM-11 and APTM-4 targets for the harmonization panel 
and sent the IVD manufacturers a preliminary report with the intention that both 
targets would be used in recalibration. Manufacturers recalibrated by value re-
assignment of their master calibrators to the APTM-11 and APTM-4 targets following 
their in-house mathematical procedure without disclosing it to us. In essence the 
process consisted of fitting the respective APTM values and instrumental response 
data for the patient samples into an equation, and solving it for concentrations as a 
function of the responses registered for the master calibrators; the process continued 
with recalculating the results for the patient samples as if the revised master 
calibrators were used for calibration. The manufacturers reported back 2 sets of 
results, i.e., recalibrated to either the APTM-11 or APTM-4. For the measurements of 
the RI panel, manufacturers also reported the pre- and post-recalibration results; the 
latter were based on mathematical transformation of the former using the master 
calibrators revised in the harmonization study. 
 
Data treatment  
For data treatment in the method comparison study, we used Microsoft EXCEL®. We 
focused on two objectives: decide which APTM (APTM-11 or APTM-4) to use as a 
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basis for harmonization, and demonstrate/validate the suitability of the recalibrated 
results to meet the analytical specifications stated below. For the first objective, we 
calculated/plotted the differences (%) between the 2 APTMs relative to their mean; in 
addition, we compared the outcome of the recalibration of the assays to each of the 
APTMs by ordinary linear regression analysis. To do so, we calculated for each 
sample the overall mean concentration from the results reported by the 
manufacturers after recalibration to the APTM-11 (Y-axis) and APTM-4 (X-axis). For 
the second objective, we considered for each assay (i) the pre- and post-recalibration 
median deviation (%) to the target in distinct concentration intervals; (ii) the mean 
deviation or bias (%) (and one-sided 95% confidence interval (CI)) to the target after 
recalibration; (iii) the pre- and post-recalibration CVs (%) of the assay means, and (iv) 
the total error (TE, %) for the first replicate after recalibration.  
For treatment of the pre- and post-recalibration data for the RI study we used 
the CBstat software (version 5.1, K. Linnet, www.cbstat.com). It comprises the 
Anderson-Darling test to assess the data for normality, before selecting the 
appropriate procedure to estimate the RI characteristics (among others, the 2.5 and 
97.5 percentiles, further referred to as lower limit (LL) and upper limit (UL), 
respectively). In addition, the software supplies the 90% CIs of the estimates. Since 
none of the datasets was normally distributed, nor after log transformation (p<0.01), 
we opted for the non-parametric bootstrap (500 replicates) procedure (25). We also 
estimated the pre- and post-recalibration overall RI, after applying the robust factor 
analysis model on the results of the 14 participating assays. To investigate the effect 
of recalibration on the uniformity of the RI characteristics, we calculated the reduction 
of the CV (%) of the assay means, and compared the pre- and post-recalibration 
medians and percentiles of the individual RIs to those of the overall RI.  
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Analytical specifications  
For validation of the recalibration data we used the desirable specifications for bias 
and TE based on the biological variation, i.e., 7.8% (bias) and 23.8% (TE) (26). 
 
Homogeneity and stability study 
We assessed the homogeneity from a subset of 12 samples (12 aliquots per sample) 
collected in parallel with the samples for the method comparison study (but not 
included in the harmonization panel). The TSH concentrations in this sample set 
were in the low, mid and high range (4 test samples per interval). Because 2 
companies had been involved in aliquoting, we did this study for both. A protocol 
described for certified reference materials was adopted (27). Note that the stability 
study is ongoing. For details on both studies, see the online Supplemental, Sections 
1 and 2.
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Results  
Concentration interval covered by the clinical samples in the method comparison 
study 
The full TSH concentration interval of the harmonization panel was from 0.001 mIU/L 
to 172 mIU/L (based on APTM-11) and 0.002 mIU/L to 193 mIU/L (based on APTM-
4). Note, the reason for the discrepancy between the highest TSH concentration 
according to the APTM-4 and APTM-11 was that, coincidentally, the 4 selected 
assays in APTM-4 all reported a more elevated measurement result. The 
concentrations in the follow-up panel were between 0.002 and 169 mIU/L (based on 
APTM-4). In the online Supplemental, Figure 1S and Figure 2S the uncertainties of 
the APTM-4 estimates are shown. The overall relative uncertainties amounted to 
0.7% (for the upper part of the CI of the estimate) and 1.0% (the lower part CI). The 
mean difference between the APTM-4 and APTM-11 targets relative to their mean 
was -0.6% (see the online Supplemental, Figure 3S). Regression analysis of the 
overall mean results calculated from the results reported by the manufacturers after 
recalibration to either the APTM-11 or APTM-4 gave [mean resultsrecal to the APTM-11] = 
0.987 [mean resultsrecal to the APTM-4] + 0.055 (R2 = 0.9999); the mean difference was -
2.2% (see the online Supplemental, Figure 4S). Based on this outcome and 
appreciating the asset of using targets inferred from the results by the 4 assays that 
measured both the harmonization and first follow-up panel in the same run (details in 
the online Supplemental, Section 13), we decided to use the APTM-4 for 
recalibration.  
 
Validation of the effectiveness of recalibration  
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Only the results within the assays’ claimed measurement intervals were used (see 
Table 1). The combined difference (%) plots (Figure 1A and Figure 1B) show the 
assays’ deviations to the APTM-4 before (Figure 1A) and after recalibration (Figure 
1B). Note, the latter was constructed using the measurement data mathematically 
recalculated with the re-assigned master calibrators. Figure 2A and Figure 2B 
demonstrate the assay-specific median deviations (%) to the APTM-4 before and 
after recalibration in 3 concentration intervals. Figure 2A shows the combined picture 
of the deviations with indication of the 15th, 50th and 85th centiles, while Figure 2B 
represents for each assay the magnitude and sign of the deviations. From the details 
listed in the online Supplemental, Table 3S, one can see that before recalibration, the 
median deviations ranged from -41% (D) to +23% (C) (<0.5 mIU/L), -15% (L) to 
+19% (C) (≥0.5 mIU/L to 5 mIU/L) and -14% (B, L) to 8% (C) (≥5 mIU/L), hence, the 
deviations of the most discrepant assay pairs (D & C, L & C, and B/L & C) were 
respectively 64%, 34% and 22% apart from each other. After recalibration, the 
ranges of the median deviations were reduced, from -20.7% (K) to +16% (I), -8.0% 
(H) to +7% (B), -7% (C) to 6% (O), respectively.  
Figure 3 shows that the bias (%) (and one-sided 95% CI) of 13 of the 14 
recalibrated TSH assays met the specification of 7.8%. For assay H (bias: -6.6%) the 
specification was not met with 95% confidence (28) (for details on the interpretation, 
see the online Supplemental, Table 4S). 
Recalibration reduced the CV of the assay means for the harmonization panel 
from 9.5% to 4.2% (concentration interval from 0.5 mIU/L to 5.0 mIU/L) and from 
7.5% to 4.4% (concentration interval between 0.0175 mIU/L and 74 mIU/L. The CV 
profile for the larger interval is shown in the online Supplemental, Figure 5SA. In 
terms of TE, 8 of the recalibrated TSH assays (A, B, D, F, I, J, L, N) met the 
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specification (less than 5% of the differences 23.8%), while for the other 6 assays, 
7% to 15% were outside the limits (Figure 4). 
 
Reference interval study  
Figure 5 gives an overview of the medians and percentiles (both with the 90% CIs) of 
the overall and individual RIs before and after recalibration (data available in the 
online Supplemental, Table 5S). Figure 5 shows how the uniformity of the RIs 
(medians and percentiles) was improved by recalibration, as the latter narrowed the 
ranges of the medians by approximately one third (expressed relative to the median 
of the overall RI). The range before recalibration was from 1.20 mIU/L (assay N) to 
2.09 mIU/L (assay C), and after recalibration was from 1.58 mIU/L (assay N) to 1.87 
mIU/L (assay O). The Supplemental Table 5S shows a similar effect of recalibration 
on the percentiles. Before recalibration the maximum deviations for the LL and UL 
amounted to 53% and 51% (assays C and N), while after recalibration the most 
deviating assays were 21% apart from each other for the LL (assays I and N) and 
18% for the UL (assays O and N). Recalibration also considerably reduced the CV 
(%) of the assay means for the RI measurements, i.e., from 11.9% to 4.8% (see also 
the online Supplemental, Figure 5SB). This reduction in CV for the RI panel 
compared well with the CV decrease observed for the same concentration interval of 
the harmonization panel.  
  
Homogeneity study  
Statistical testing confirmed that the hypothesis of homogeneity of the samples in the 
3 panels could be accepted (p>0.05, see the online Supplemental, Section 1 for 
details). 
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Discussion  
Our attempt to harmonize commercially available TSH immunoassays began with a 
method comparison using specimens from presumably healthy individuals (Phase I), 
in which we showed that recalibration using the APTM significantly increased the 
agreement of commercially available assays (29). Allowing the manufacturers to 
individually adjust their own calibrators using the APTM from another method 
comparison with a similar panel of euthyroid specimens (Phase II) established a 
proof-of-concept that the approach to harmonization was feasible (30). Recalibration 
to the APTM was similarly successful using specimens from patients with thyroid 
disease (Phase III). In addition, the overall excellent correlation of most of the 
immunoassays’ results to the APTM in patients with both hypo- and hyperthyroidism 
led the committee to conclude that the assays measured TSH in an equimolar 
fashion, regardless of differences in glycosylation (31). This report describes our next 
step (Phase IV), in which we attempt to show that our approach for recalibration may 
allow manufacturers to have more uniform RIs in the future. Note that the 
participating manufacturers who only recently joined our effort successfully went 
through the “step-up” approach previously described (32). 
The panel of commutable samples used for recalibration in this round had 
fairly uniformly distributed concentrations within the typical measurement intervals. 
Eleven out of the 14 assays had pre-harmonization median deviations within 10% 
from the APTM. The improved agreement after recalibration is shown by centering of 
the assays’ differences (%) around zero difference from the APTM-4 targets, by the 
reduced differences (%) of the 15th and 85th centiles and the mean deviations (%) 
meeting the 7.8% bias specification with 95% confidence for 13 out of 14 assays. 
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Another indicator of successful recalibration was the reduction of the CV (%) of the 
assay means for the harmonization panel from 9.5% to 4.2%, and for the RI panel 
from 11.9% to 4.8%.  
Because a minimum of 6 months passed between recalibration of the assays 
and testing of the RI specimens, several manufacturers assayed the latter using 
different reagent lots (12 of 14), different calibrator lots (10), or different instruments 
(8). This may have contributed to the observed differences of the individual RI 
percentiles from the reference ones.  
We believe that this study provides evidence that harmonization may make it 
possible for manufacturers to achieve more uniform RIs in the near future. However, 
we wish to emphasize that the RI presented in this report cannot be seen as the 
endpoint. It is important that all involved stakeholders understand that uniform RIs 
does not mean “one size fits all-RI”. Reference intervals may be impacted by factors 
such as age, ethnicity, iodine intake, etc. IVD manufacturers will need to verify their 
individual RIs for TSH in accordance with accepted consensus standards, such as 
those from the IFCC, the National Academy of Clinical Biochemistry and the Clinical 
and Laboratory Standards institute (33-35). 
It will also be important that the traceability anchor achieved through this study 
is sustained by providing follow-up panels with traceability to the very first 
harmonization panel. We set already an important step in this direction by ensuring 
the perfect link between the first follow-up and harmonization panel (through the 
target setting of both panels in parallel). For the future, we intend to always develop a 
new panel before depletion of the previous one, and measure both in overlap. 
Whether the 4 assays selected here will do the future target setting, will depend on 
their long-term stability. We will assess this by our Percentiler application described 
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elsewhere (36). Also, collaboration with proficiency testing organizers using 
commutable samples will be important to provide surveillance of the continuing 
relationship among different assays. 
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1 
Tables 2 
 3 
Table 1: Study participants (ordered by code given in this report), inclusive the platforms/TSH assays and number of 4 
samples considered for validation of the recalibration process. The listed reference and measurement intervals are those 5 
stated in the kit inserts.  6 
IVD manufacturer 
Platform/Immunoassay 
Code Reference Interval (mIU/L) 
Measurement 
Interval (mIU/L)e 
Ng 
 
Siemens Healthineers (Tarrytown, NY) 
Advia Centaur XP 
Ac,d 0.55 - 4.78 (n = 229) 0.008 - 150 89 
Abbott Diagnostics (Abbott Park, IL) 
Architect i2000 
Bc,d 0.35 - 4.94 (99%, n = 549) 0.010 – 100 88 
aShenzhen Mindray Bio-Medical Electronics Co., Ltd. 
(Shenzhen, China) 
CL-2000i 
Cd 0.35 – 5.10 0.020 - 100 87 
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Ortho-Clinical Diagnostics (Buckinghamshire, UK) 
Vitros ECi 
Dd 0.47 - 4.68 (95%, n = 525) 0.015 - 100 85 
bioMérieux SA (Marcy-l’Etoile, France) 
Vidas 
E 0.25 - 5.00 (n = 60) 0.050f – 60.0 77 
Beckman Coulter Inc. (Brea, CA) 
Access 2 
Fd 0.34 - 5.60 (95%, n = 217) 0.015 - 100 86 
DiaSorin S.p.A (Saluggia, Italy) 
Liaison® Analyser 
Gd 0.30 - 3.60 (95%, n = 519) 0.020 - 100 90 
aSichuan Maccura Biotechnology Co., Ltd (Chengdu, China) 
IS1200 
 
Hd 
 
0.30 - 4.04 (95%, n = 146, 
Chinese) 
0.37 - 3.76 (95%, n = 299, 
Europeans) 
 
 
0.020 - 100 
 
86 
Roche Diagnostics GmbH (Mannheim, Germany) 
Elecsys (Cobas e 601) 
Ic,d 0.27 - 4.20 (95%, n = 516) 0.014 - 100 88 
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Tosoh Corporation (Tokyo, Japan) 
AIA-2000 
Jc,d 0.38 - 4.31 (95%, n = 497) 0.010 - 100 89 
aSnibe Co., Ltd. (Shenzhen, China) 
Maglumi 2000 
Kd 0.30 - 4.50 (95%) 0.020 - 100 87 
aFujirebio Inc. (Tokyo, Japan) 
Lumipulse G1200 
Ld 0.31 - 3.07 (95%, n = 140)  0.0042f - 200 90 
bLSI Medience Corporation (Tokyo, Japan) 
STACIA 
N 0.48 - 4.15 0.002f - 100 88 
bSysmex Corporation (Kobe, Japan) 
HISCL-5000 
O 0.34 - 4.22 (n = 134) 0.002 - 100 91 
a,bManufacturers who only joined in 2015a and/or 2016b for participation in the Phase IV method comparison study. 7 
cData from these manufacturers were used to calculate the APTM-4. 8 
dData from these manufacturers were used to calculate the APTM-11. 9 
eThe lower limit of the measurement intervals is the functional sensitivity unless differently stated as flimit of quantitation defined by 10 
CLSI’s EP17 (24). 11 
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gActual number of samples taken into consideration in the validation of the recalibration [this number was related to each assay’s 12 
measurement interval and was maximum 101 (total number of samples in the harmonization panel)].  13 
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Figure Captions 
 
 
Figure 1: Combined difference (%) plots to the APTM-4 before (A) and after 
recalibration (B).  
For each assay and sample, the difference of the mean from duplicate 
measurements is plotted. The differences of the most discrepant assays before 
recalibration are highlighted by filled and colored circles: assay C, red (highest 
positive mean difference at ~15%), assay L, blue (highest negative mean difference 
at -16.5%); those of all other assays are shown by open black circles. For the sake of 
resolution, the plots do not include samples with a % difference beyond ±85% (13 
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and 10 samples before and after recalibration, respectively). The red broken lines are 
the 7.8% bias limits based on biological variation; the blue broken lines represent the 
15th and 85th centiles. Note that as a result of recalibration, the symbols of the most 
discrepant assays are centered around zero % difference, and that the % differences 
of the centiles are reduced by one third. 
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Figure 2: Median deviations (%) of the assays to the APTM-4 before and after 
recalibration in 3 concentration intervals: low: <0.5 mIU/L, mid: 0.5 <5.0 mIU/L, 
high: 5.0 mIU/L. 
 
 
34 
 
(A) summarizes the overall improvement in terms of the median deviations (%) by 
recalibration. For each concentration interval, 2 pairs of data are shown; the black 
and red dots show the combined assay-specific median deviations before and after 
recalibration, respectively; the lines represent their 15th, 50th and 85th centiles. (B) 
represents the median deviations (%) of each individual assay by a pair of bars; the 
upper and lower bar shows the median deviation before and after recalibration. Note 
that the bars show the unsigned magnitudes, but the colors represent the signs (blue: 
negative, red: positive). Note, for assay A (> 5 mIU/L) the deviations were zero. 
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Figure 3: Difference (%) plots after recalibration of the assays to the APTM-4. 
The red broken lines are the bias limits of 7.8%, while the blue full lines represent 
each assay’s mean deviation or bias (%) for the claimed measurement interval 
(detailed in Table 1). The short and parallel blue lines (left in the plots) represent the 
limits of the one-sided 95% CI of the bias. Note that the samples for which the 
deviation was beyond 80% were not included in the % difference plots; they are 
identified in the respective graphs by their concentration and % difference. To avoid 
confusion: the concentration given in the graph is based on the APTM-4, for which 
the concerned assay reported a result within its measurement interval. 
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Figure 4: Total error (%) plots of the first replicate after recalibration to the 
APTM-4. The TE was estimated from the % difference to the APTM-4 of the first 
replicate after recalibration. It was validated against the 23.8% specification derived 
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from the biological variation (red broken lines). The 95% limits of agreement (mean % 
difference ±1.96 CVdiff (%); blue broken lines) emphasize the fact that the magnitude 
of the scatter in the plots is different from assay to assay. Note that to keep the 
resolution of the graphs reasonable, the samples for which the deviation was beyond 
80% were not included, but are identified in the respective graphs by their 
concentration and % difference. To avoid confusion: the given concentration is based 
on the APTM-4, for which the concerned assay reported a result within its 
measurement interval.  
 
Figure 5: Comparison of the pre- and post-recalibration reference intervals of 
the individual immunoassays to the overall RI (n = 120). 
The pre- and post-recalibration RI characteristics are shown in green and blue, 
respectively; the thick horizontal bars for each assay stand for the 2.5th , 50th and 
97.5th percentiles, while the thin vertical lines represent the 90% CIs of the respective 
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percentiles. The grey and blue broken horizontal lines stand for the post-recalibration 
2.5th , 50th and 97.5th reference percentiles and their respective 90% CIs.  
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1 Details of the homogeneity study 
As mentioned in the main text, we used for the homogeneity study the protocol described for 
certified reference materials of the European Commission (Ref. 27 in the main text). Note 
that one of the IVD manufacturers volunteered to perform measurements for the 
homogeneity study, i.e., Roche with the Cobas Elecsys TSH. Of the 12 aliquots per sample, 
4 were randomly selected and pooled; 8 measurements were done for this pool. The 
remaining 8 aliquots were measured in singleton. All measurements (of the individual 
aliquots and the pool) were done in an alternating sequence, within run. The combined data 
were tested for outliers with a Grubbs test. Then the variances of the measurement data for 
the pool and the individual aliquots were assessed for significant difference by means of an 
F-test (95% confidence level) (see table below). 
Table 1S: Summary of the results of the homogeneity study. 
Sample ID Mean (mIU/L) 
(aliquots) 
CV (%) 
(aliquots) 
Mean (mIU/L) 
(pool) 
CV (%) 
(pool) 
p (F-test, 95% CLa) 
1 1.681 0.6 1.713 0.6 0.9 
2 2.604 0.7 2.647 0.4 0.3 
3 25.23 0.5 25.71 0.3 0.4 
4 67.39 0.4 68.58 0.5 0.7 
5 0.008 10.7 0.009 9.6 1.0 
6 0 N/Ab 0 N/A N/A 
7 0.981 0.8 0.989 0.7 0.4 
8 0.031 2.3 0.031 2.5 0.9 
9 0.703 0.7 0.681 0.5 0.3 
 
 
43 
 
10 5.374 0.6 5.318 0.9 0.4 
11 0.241c 1.1 0.241 1.5 0.6 
12 10.53 0.9 10.47 0.5 0.2 
aCL: confidence level 
b: N/A: not applicable 
c: 1 Outlier identified with the Grubbs test 
2 Details of the stability study 
The stability study has already started, but will last in total 2 and 5 years. For each panel, 9 
samples in total (3 times 3 with a concentration in the hypo-, eu- and hyperthyroid range, 
respectively) will be stored for different time periods at the effective storage temperature (-
70°C) or at the reference temperature (liquid N2). Storage is done in the facilities of the 
National Institute for Biological Standards and Control. Note that the samples were collected 
as described for the homogeneity study in the main text. The time storage points are 0, 8, 16 
and 24 months (2 year study) or 0, 36, 48 and 60 months (5 year study). To avoid any 
complications due to measurement errors/variation, all samples will be measured within-run 
at the end of each study. A schematic overview of the design of the stability study is given in 
Table 1S: at time points 8 and 16 or 36 and 48, one box of samples will be moved from the 
reference to the storage temperature. 
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Table 2S: Stability study: experimental set-up for storage of the samples.  
Sample 0-8 months 8-16 months 16-24 months 
A1-ref 1 Store at L N2 Store at L N2 Store at L N2 
A2-ref 1 Store at L N2 Store at L N2 Store at L N2 
A1-t1 1 Store at L N2 Store at L N2 Store at -70°C 
A2-t1 1 Store at L N2 Store at L N2 Store at -70°C 
A1-t2 1 Store at L N2 Store at -70°C Store at -70°C 
A2-t2 1 Store at L N2 Store at -70°C Store at -70°C 
A1-t3 1 Store at -70°C Store at -70°C Store at -70°C 
A2-t3 1 Store at -70°C Store at -70°C Store at -70°C 
Sample 0-36 months 36-48 months 48-60 months 
A1-ref 2 Store at L N2 Store at L N2 Store at L N2 
A2-ref 2 Store at L N2 Store at L N2 Store at L N2 
A1-t1 2 Store at L N2 Store at L N2 Store at -70°C 
A2-t1 2 Store at L N2 Store at L N2 Store at -70°C 
A1-t2 2 Store at L N2 Store at -70°C Store at -70°C 
A2-t2 2 Store at L N2 Store at -70°C Store at -70°C 
A1-t3 2 Store at -70°C Store at -70°C Store at -70°C 
A2-t3 2 Store at -70°C Store at -70°C Store at -70°C 
Note: A stands for aliquot; L N2 for liquid nitrogen. 
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3 Sample sourcing – Eligibility and exclusion criteria  
Inclusion criteria: -Individuals are at least 18 years old and competent to give informed 
consent, as considered by the physician, study nurse or other health 
care professional interviewing the patient.  
-Individuals being evaluated for a thyroid disorder and classified into 
one of the following groups (if possible evenly distributed): 
 A: Hyperthyroid (n = 30) 
A1: 10 patients with suppressed TSH, around 0.01 mIU/L 
A2: 10 patients with TSH values between 0.01 – 0.1 mIU/L 
A3: 10 patients with TSH values between 0.1 – 0.3* mIU/L 
 
 B: Euthyroid (n = 30) 
Patients with TSH values between 0.3 – 3.0 mIU/L* 
 
 C: Hypothyroid (n = 40) 
C1: 20 patients with TSH values between 3.0 – 50 mIU/L*  
C2: 20 patients with TSH values > 50 mIU/L up to 100 mIU/L. 
 Donors treated for thyroid dysfunction can be included, provided 
information on the type of treatment and start of the treatment is 
available.  
Exclusion Criteria -Those individuals previously enrolled into this clinical study. 
-Individuals diagnosed with a severe non-thyroidal illness (NTI), 
defined as a state of dysregulation where levels of T3, T4, FT3 
and/or FT4 are abnormal although the thyroid gland does not appear 
to be dysfunctional. In practice, NTI is reported to be usually 
associated with critical illness or starvation. Examples: chronic renal 
failure, liver cirrhosis, advanced (active) malignancy, sepsis, trauma, 
prolonged fasting or starvation, heart failure, MI, and any psychiatric 
disorder. 
-Individuals with known pregnancy. 
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-Those patients not meeting the established inclusion criteria. 
*Note: these values are only indicative because they depend on the measurement range and 
the reference interval of the assay used to evaluate the TSH status. 
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4 Uncertainty of the APTM targets 
Figure 1S: Plots showing the uncertainties of the statistically estimated APTM-4 target 
values for the TSH harmonization panel. The uncertainty for each target value was estimated 
by use of a bootstrapping procedure (n = 1500) with sampling from the distribution of data 
used in the robust factor analysis model for deriving the APTM (Ref. 22 in the main text). 
This procedure provided for each APTM estimate the 95% confidence interval, which was 
used as a measure of the uncertainty. The reason why the bootstrap simulations leads to 
asymmetric uncertainties is that the results by the different assays per individual sample 
were not normally distributed around that APTM, e.g., when more assays gave for a certain 
sample a higher concentration than the estimated APTM, or when 1 assay gave a much 
higher (or lower) value than the other assays for a certain sample, the uncertainty was 
broader at the positive side (and vice versa). To better visualize the relative magnitudes of 
the uncertainties, we plotted them for the samples sorted by increasing but normalized 
concentration (concentration/concentration); the horizontal bars represent for each sample 
the upper and lower limit of 95% confidence interval around the APTM estimate expressed 
as ratio to the estimate to which both relate. We finally estimated the overall uncertainty (%) 
from the mean of the relative uncertainties at both sides of the APTM targets, which 
amounted to 0.9% (lower limit) and 0.7% (upper limit). Note: 1) the plotted data are for 
samples with concentrations above the mean of the assays’ lower limits of the stated 
measurement intervals (0.0175 mIU/L; for the individually claimed measurement intervals, 
see Table 1 in the main text); 2) the uncertainty of the APTM-11 was similar (not shown, 
because we decided to only use the APTM-4; see “Results” in the main text).  
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Figure 2S: Similar plot as above but for the first follow-up panel. The mean of the relative 
uncertainties at both sides of the APTM-4 targets amounted to 1.1% (lower limit) and 0.7% 
(upper limit).  
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5 Comparison of the APTM targets 
Figure 3S: Difference (%) plot of the targets based on the APTM-4 and APTM-11 
relative to their mean.  
  
 
 
50 
 
 
6 Comparison of the recalibration to the APTM-11 and APTM-4  
Figure 4S: (A) shows the overall mean concentrations of the samples after recalibration of 
the assays to the APTM-11 (Y-axis; log) plotted to those after recalibration to the APTM-4 (X-
axis; log), as well as the ordinary linear regression equation (with R2); note that each data 
point represents the overall mean concentration for a sample calculated from 14 mean 
concentrations per recalibrated assay (“mean” concentrations because each sample had 
been measured in duplicate by the respective assays); as described in the main text each 
manufacturer mathematically recalibrated and reported back 2 sets of measurement results 
as if his assay was recalibrated either to the APTM-4 (X-axis) or APTM-11 target (Y-axis); (B) 
plots the data as % difference (mean of means recalibrated to the APTM-4 minus those 
recalibrated to the APTM-11) relative to their mean. Note that for this comparison, we used 
all reported results. 
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7 Assay-specific median deviations (%) (pre- and post-recalibration) 
 
Table 3S: Median deviations (%) of each of the immunoassays to the APTM-4 before and after recalibration in distinct concentration 
intervals. 
Assays Before recalibration After recalibration 
<0.5 mIU/L ≥0.5 <5 mIU/L ≥5 mIU/L <0.5 mIU/L ≥0.5 <5 mIU/L ≥5 mIU/L 
A -0.6 -1.6 0.0 -0.6 -1.6 0.0 
B -9.4 -7.0 -14.0 1.8 4.5 -3.4 
C 23.0 19.4 8.3 6.6 2.6 -6.9 
D -41.4 1.0 1.0 -0.3 1.5 -0.2 
E -23.4 7.2 6.7 -9.5 -1.5 -2.3 
F -11.3 -9.5 -6.8 -5.9 -6.5 -1.9 
G -3.6 -4.3 -3.3 4.3 0.5 -1.8 
H -10.7 -11.8 1.0 -6.2 -8.4 1.8 
I 9.1 3.1 4.7 15.9 2.0 -2.9 
J 3.0 4.5 3.0 -1.1 0.4 -1.1 
K -19.4 -5.9 0.7 -20.7 -0.4 -0.8 
L -23.8 -15.4 -14.3 1.0 -0.5 2.5 
N -10.1 -14.9 -12.0 5.6 -5.4 3.1 
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O -11.3 -5.4 -4.6 -0.1 7.1 6.3 
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8 Post-recalibration biases (%) 
Table 4S: Assay biases (%) and one-sided 95% confidence interval (CI) after 
recalibration to the APTM-4, and their assessment against the specification of 7.8% 
inferred from the biological variation.  
Assay  Bias1 (%) One-sided2  
95% CI (%) 
Upper bias 
limit (%)  
(Bias + CI) 
Lower bias 
 Limit (%)  
(Bias – CI) 
A -1.8 1.0 -0.8 -2.8 
B 2.6 1.6 4.2 1.0 
C -0.8 3.2 2.4 -4.0 
D 1.5 1.4 2.9 0.1 
E -3.6 2.4 -1.2 -5.9 
F -5.8 1.6 -4.2 -7.4 
G -0.7 2.2 1.5 -2.9 
H -6.6 2.5 -4.1 -9.1 
I 4.3 2.0 6.3 2.3 
J 0.3 0.8 1.1 -0.6 
K -4.3 3.5 -0.8 -7.7 
L 1.4 1.4 2.9 0.0 
N -0.1 2.5 2.4 -2.6 
O 3.7 2.3 6.0 1.5 
1The bias (%) is the mean of the deviations (%) calculated for the claimed measurement 
ranges.  
2One-sided t-values (obtained from Excel with the function TINV(0.1, df)) were used for 
calculation of the CI. 
Interpretation (Ref. 28 in the main text): for 13 of the 14 assays it can be confidently asserted 
that their bias meets the 7.8% specification with a 95% probability; for assay H, in spite of a 
bias of -6.6%, it is not possible to state this with 95% confidence, because the lower limit of 
the one-sided 95% CI (colored cell) violates the -7.8% limit.  
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9 CV (%) reduction 
Figure 5S: Profile showing the between assay CV (%) (CV calculated from the assay 
means) for the harmonization panel before and after recalibration, (A) for the concentration 
interval from 0.0175 mIU/L to 74 mIU/L (note these limits represent the mean of the LL of the 
claimed measurement ranges and the second highest concentration in the panel; this range 
shows that the CVs are constant from a concentration of approximately 0.5 mIU/L on), (B) for 
the concentration range covered by the reference interval panel. The black squares stand for 
the CV of each individual sample before recalibration, the red triangles after recalibration; the 
dotted lines in A & B were constructed to fit the data points and match with the median CV 
per sample over all assays.  
 
A 
B 
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10 Reference interval study  
 
Table 5S: Characteristics of the overall and individual TSH reference intervals 
before and after recalibration of the immunoassays.  
ID Median [90% CI] Width RI LL [90% CI] UL [90% CI] 1LL 1UL 
 (mIU/L) (%) 
Before recalibration 
Overall 1.70 [1.60-1.82] 3.63 0.51 [0.40 - 0.63] 4.14 [2.81 - 5.48]   
A 1.73 [1.57-1.86] 3.69 0.54 [0.42 - 0.66] 4.23 [2.86 - 5.60] 5.4 2.1 
B 1.61 [1.51-1.71] 3.37 0.51 [0.40 - 0.62] 3.88 [2.64 - 5.11] -1.2 -6.5 
C 2.09 [2.02-2.29] 4.50 0.63 [0.42 - 0.85] 5.14 [3.82 – 6.45] 23.4 23.9 
D 1.75 [1.62-1.93] 3.55 0.50 [0.36 - 0.63] 4.05 [3.07 - 5.03] -3.4 -2.4 
E 1.73 [1.61-1.86] 3.83 0.49 [0.33 - 0.64] 4.32 [2.78 - 5.87] -4.8 4.3 
F 1.79 [1.64-1.94] 3.89 0.52 [0.40 - 0.65] 4.41 [2.81 - 6.01] 1.9 6.4 
G 1.74 [1.62-1.87] 3.73 0.57 [0.45 - 0.70] 4.30 [2.89 - 5.71] 11.7 3.7 
H 1.67 [1.51-1.87] 4.07 0.47 [0.31 - 0.62] 4.53 [2.97 - 6.09] -9.4 9.3 
I 1.88 [1.77-1.98] 3.97 0.59 [0.45 - 0.73] 4.56 [2.87 - 6.25] 14.1 9.9 
J 2.00 [1.83-2.17] 4.31 0.61 [0.45 - 0.77] 4.92 [3.46 - 6.38] 18.3 18.6 
K 1.70 [1.56-1.80] 3.41 0.50 [0.39 - 0.61] 3.91 [2.62 - 5.20] -2.6 -5.7 
L 1.55 [1.45-1.64] 3.19 0.48 [0.37 - 0.59] 3.67 [2.51 - 4.84] -7.0 -11.5 
N 1.20 [1.10-1.29] 2.65 0.36 [0.28 - 0.44] 3.01 [1.84 - 4.17] -29.9 -27.5 
O 1.65 [1.52-1.75] 3.67 0.52 [0.4 - 0.64] 4.19 [2.83 - 5.55] 0.7 1.1 
After recalibration 
Overall 1.76 [1.65-1.90] 3.72 0.56 [0.43 - 0.69] 4.27 [2.86 - 5.69]   
A 1.73 [1.57-1.86] 3.69 0.54 [0.42 - 0.66] 4.23 [2.86 - 5.61] -3.2 -1.0 
B 1.82 [1.69-1.93] 3.79 0.57 [0.45 - 0.70] 4.36 [2.97 - 5.76] 2.4 2.1 
C 1.65 [1.60-1.81] 3.56 0.50 [0.33 - 0.67] 4.07 [3.03 - 5.11] -10.0 -4.9 
D 1.75 [1.62-1.93] 3.50 0.52 [0.39 - 0.66] 4.02 [3.05 - 5.00] -6.4 -5.9 
E 1.73 [1.61-1.85] 3.82 0.50 [0.34 - 0.65] 4.32 [2.79 - 5.85] -10.8 1.1 
F 1.84 [1.69-2.00] 4.01 0.54 [0.41 - 0.67] 4.55 [2.89 – 6.22] -3.0 6.5 
G 1.67 [1.56-1.80] 3.58 0.55 [0.43 - 0.67] 4.13 [2.78 - 5.48] -1.3 -3.5 
H 1.73 [1.59-1.91] 3.86 0.51 [0.34 - 0.68] 4.38 [2.91 - 5.84] -8.3 2.4 
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ID Median [90% CI] Width RI LL [90% CI] UL [90% CI] 1LL 1UL 
 (mIU/L) (%) 
I 1.83 [1.72-1.92] 3.74 0.59 [0.45 - 0.72] 4.32 [2.77 - 5.88] 5.3 1.2 
J 1.84 [1.68-1.99] 3.96 0.56 [0.41 - 0.71] 4.52 [3.18 – 5.87] 0.4 5.8 
K 1.81 [1.66-1.93] 3.43 0.58 [0.45 - 0.72] 4.01 [2.98 - 5.04] 4.5 -6.2 
L 1.86 [1.74-1.97] 3.83 0.57 [0.44 - 0.70] 4.41 [3.01 - 5.81] 2.7 3.1 
N 1.58 [1.45-1.70] 3.49 0.47 [0.36 – 0.58] 3.97 [2.43 – 5.51] -15.6  -7.2 
O 1.87 [1.72-1.98] 4.16 0.59 [0.45 – 0.72] 4.74 [3.21 – 6.27] 4.9 10.9 
1Difference (%) compared to the overall RI LL and UL, respectively. 
Note: The colored cells indicate the ranges of the medians and the percentiles discussed in 
the main text.  
 
 
 
57 
 
 
11 Considerations before deciding to use the APTM-11 or APTM-4 
for harmonization 
Pro’s for using the APTM-11 
-The harmonization concept developed by C-STFT was based on the APTM inferred from 
the measurement results by all assays which participated in the method comparison study 
(Ref. 19).  
-Target values based on a greater number of assays are more representative, which is a 
virtue for harmonization projects. 
-All the experience in this project up to now is based on the APTM estimated from the 
measurement results by all participating manufacturers. 
-According to this APTM concept, all manufacturers are and feel equivalent partners in the 
harmonization process and equally contribute, provided their assay’s measurement range 
covers the concentration range of the method comparison samples and their measurement 
results correlate sufficiently well with the APTM. However, as described in the main text, in 
this study with 14 participants, we had already to deviate. Indeed, we calculated the APTM-
11, because for one manufacturer the assay design was not real 3rd generation, and another 
2 manufacturers joined the project 1 year after completion of the validation of the target 
setting. Also for the future, new manufacturers who use the follow-up panel will have to 
accept that they did not contribute to the target setting.  
 
Con’s against the APTM-11 
The more assays that participate in the target setting of a panel with samples for which a 
only a restricted volume is available (inherent for a project based on samples from patients), 
the more sample volume is consumed. For example, in this study with duplicate 
measurement by 14 assays, the harmonization panel was almost depleted. This would be of 
particular concern for the follow-up panel, which for obvious reasons should remain with as 
many sample aliquots as possible after target setting. Therefore, it was clear from the 
 
 
58 
 
beginning of the harmonization activity that the target setting of the follow-up panel should be 
done with fewer assays. This decision required that the following questions be answered: 
-How many assays to select for the reduced target setting protocol? 
-Which criteria to use for the selection? 
-Will the APTM from fewer assays be biased vis-à-vis the APTM from more assays? 
-How to ensure that the selected assays are stable in time, so that they can be used for 
target setting of the future follow-up panels? 
The study was designed to be able to answer most of the above questions. In short, the 
design can be described as follows. 
-For the harmonization panel (n = 101 samples) the APTM-11 was calculated from the 
measurement results by 11 assays.  
-Four assays were selected for measuring the first follow-up panel (n = 95) and the 
harmonization panel, both in the same run.  
-The key criteria for the selection of assays were the assays’ performance in the Phase III 
study; and select assays on the basis of results that were symmetrically located about the 
APTM with, in addition, a low scatter.  
-The APTM-4 was calculated from the double sample size (n = 196) using both follow-up and 
harmonization samples compared to the APTM-11.  
-The bias between the APTM-11 and APTM-4 targets was assessed, as well as the outcome 
of recalibration of all assays against both targets.  
 
The conclusions reached in this study to the above questions were:  
-using 4 assays for target setting is sufficient; 
-the validity of the selection criteria is confirmed;  
- the mean difference between the APTM-4 and APTM-11 targets is only -0.6%;  
-regression analysis of the means of means by the immunoassays recalibrated to both APTM 
targets gives a mean difference of only -2.2%. 
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Additional pro’s for the APTM-4 confirmed by this study 
-The APTM-4 calculated from the double sample size ensures a lower level of uncertainty. 
-The target setting establishes the link between the harmonization and first follow-up panel, 
so that the traceability of the latter to the very first harmonization basis is a fact. Note that 
without this link, traceability would most probably have required a value transfer from the 
harmonization to the follow-up panel causing additional uncertainty. 
-Both panels start with the same low level of uncertainty. 
 
Potential con’s against the APTM-4 resulting from this study  
Application of the APTM-11 on APTM-4 regression equation, y = 0.9867 x + 
0.0546 mIU/L, at TSH reference limits, for example, those ultimately obtained in the study, 
namely, 0.56 and 4.27 mIU/L, predicts essentially no change at the upper limit, but at the 
lower limit an increase of 8 or 9%. This change exceeds the mean deviations which can be 
explained by noise due to the assay variability currently tolerated by IVD manufacturers 
(approximately 5% in the mean), but also the “desirable specification” for bias (7.8%).  
Open question that still needs to be answered 
-Will it be possible to use the 4 assays selected here to set the APTM-4 target for future 
follow-up panels? This decision will depend on the stability of the long-term performance of 
the assays. It is our plan to assess stability by our Percentiler application described 
elsewhere (Ref. 36). The decision will also require that the concerned manufacturers 
transparently communicate on relevant assay changes.  
-It might be that the current concept works over several years. However, if one day it is 
necessary, the harmonization exercise can be repeated.   
 
Final conclusion taken by the C-STFT and its IVD partners 
It is obvious that the choice between the two sets of TSH value assignments involved 
competing considerations (pro’s – con’s) and finally had to be decided pragmatically. The 
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considerations were openly discussed in a meeting where nearly all IVD partners were 
present. They unanimously agreed to the decision to recalibrate to the APTM-4. The 
following facts were accorded most relative weight in the decision: 
-the good comparability between the APTM-11 and APTM-4; 
-more aliquots are retained in the follow-up panel targeted by only 4 assays; 
-the link established between the first follow-up and harmonization panel (both were 
assigned with targets (APTM-4) in parallel) assures full traceability of the former to the latter; 
in addition, both have the same level of uncertainty.  
For the future, it will be important that a new follow-up panel is always developed before 
depletion of the previous one, whereby both are measured in overlap. 
 
